Profile data is unavailable for this security.
About the company
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
- Revenue in USD (TTM)0.00
- Net income in USD-17.48m
- Incorporated2013
- Employees13.00
- LocationBioVie Inc680 W NYE LANE, SUITE 201CARSON CITY 89703United StatesUSA
- Phone+1 (775) 888-3162
- Websitehttps://www.bioviepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ernexa Therapeutics Inc | 1.00k | -18.36m | 8.60m | 6.00 | -- | 0.6554 | -- | 8,598.35 | -5.32 | -5.32 | 0.0002 | 0.4548 | 0.0001 | -- | 0.0059 | 166.67 | -264.07 | -187.10 | -2,044.59 | -237.72 | 100.00 | -- | -1,834,000.00 | -3,375.91 | -- | -2.73 | 0.00 | -- | 755.88 | -50.61 | -105.47 | -- | -19.54 | -- |
| Cardio Diagnostics Holdings Inc | 15.79k | -6.55m | 8.66m | 13.00 | -- | 1.03 | -- | 548.16 | -4.07 | -4.07 | 0.0097 | 4.61 | 0.0024 | -- | 1.25 | 1,214.62 | -98.75 | -- | -104.31 | -- | -- | -- | -41,495.31 | -- | -- | -440.22 | 0.00 | -- | 104.39 | -- | -0.079 | -- | -- | -- |
| Liminatus Pharma Inc | 0.00 | -2.27m | 9.05m | -- | -- | -- | -- | -- | -0.0872 | -0.0872 | 0.00 | -0.0608 | 0.00 | -- | -- | -- | -77.46 | -- | -- | -- | -- | -- | -- | -- | -- | -12.30 | -- | -- | -- | -- | 28.85 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -27.16m | 9.40m | 7.00 | -- | 5.99 | -- | -- | -354.09 | -354.09 | 0.00 | 1.71 | 0.00 | -- | -- | 0.00 | -592.26 | -153.21 | -1,387.56 | -219.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.49 | -- | -- | -- |
| Lunai Bioworks Inc | 0.00 | -125.52m | 9.55m | 29.00 | -- | -- | -- | -- | -7.14 | -7.14 | 0.00 | -0.5602 | 0.00 | -- | -- | 0.00 | -212.74 | -75.79 | -361.75 | -85.18 | -- | -- | -- | -- | -- | -23.72 | -- | -- | -- | -- | -101.31 | -- | -- | -- |
| Inotiv Inc | 514.03m | -69.37m | 9.78m | 1.95k | -- | 0.0897 | -- | 0.019 | -2.02 | -2.02 | 15.00 | 3.17 | 0.6821 | 10.37 | 7.71 | 264,281.20 | -9.21 | -18.23 | -16.14 | -23.64 | 23.49 | 26.43 | -13.50 | -27.50 | 0.2218 | -0.6298 | 0.7918 | -- | 4.54 | 53.36 | 36.72 | -- | 21.79 | -- |
| LianBio - ADR | 0.00 | -87.98m | 9.83m | 163.00 | -- | 0.0482 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Imunon Inc | 0.00 | -14.33m | 10.01m | 25.00 | -- | 2.66 | -- | -- | -10.20 | -10.20 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -122.58 | -57.72 | -208.59 | -70.83 | -- | -- | -- | -7,752.42 | -- | -- | 0.00 | -- | -- | -- | 4.58 | -- | -38.98 | -- |
| BioVie Inc | 0.00 | -17.48m | 10.33m | 13.00 | -- | 0.5363 | -- | -- | -5.13 | -5.13 | 0.00 | 2.55 | 0.00 | -- | -- | 0.00 | -72.35 | -260.69 | -79.73 | -454.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.73 | -- | -- | -- |
| OSR Holdings Inc | 2.52m | -15.21m | 10.35m | -- | -- | 0.1161 | -- | 4.10 | -1.73 | -1.73 | 0.1939 | 3.46 | 0.0255 | -- | -- | -- | -22.03 | -- | -34.38 | -- | 18.35 | -- | -864.91 | -- | 0.2009 | -- | 0.0313 | -- | -- | -- | -697.08 | -- | -- | -- |
| Ainos Inc | 113.04k | -14.96m | 10.75m | 44.00 | -- | 0.7349 | -- | 95.13 | -4.29 | -4.29 | 0.0307 | 2.10 | 0.0042 | 0.12 | 3,768.00 | 2,569.09 | -55.34 | -38.46 | -60.63 | -55.22 | 82.62 | 35.93 | -13,231.35 | -1,122.70 | 2.67 | -19.92 | 0.5227 | -- | -83.02 | 12.06 | -7.93 | -- | 10.22 | -- |
| Phio Pharmaceuticals Corp | 0.00 | -7.95m | 10.87m | 5.00 | -- | 0.5938 | -- | -- | -2.73 | -2.73 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -91.57 | -73.65 | -107.58 | -86.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.96 | -- | -57.49 | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -10.09m | 11.04m | 16.00 | -- | 0.9827 | -- | -- | -5.87 | -5.87 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -60.63 | -- | -72.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Soligenix Inc | 0.00 | -11.46m | 11.50m | 14.00 | -- | 1.48 | -- | -- | -3.66 | -3.66 | 0.00 | 0.7705 | 0.00 | -- | -- | 0.00 | -105.25 | -73.79 | -165.82 | -151.46 | -- | 22.19 | -- | -1,147.93 | -- | -- | 0.00 | -- | -85.78 | -51.89 | -34.62 | -- | -- | -- |
| Longeveron Inc | 1.44m | -21.34m | 11.91m | 25.00 | -- | 1.18 | -- | 8.29 | -1.34 | -1.34 | 0.0909 | 0.4732 | 0.0632 | -- | 6.65 | 57,480.00 | -93.88 | -70.26 | -114.04 | -83.92 | 74.88 | 44.57 | -1,485.11 | -683.81 | -- | -- | 0.00 | -- | 237.38 | -15.76 | -10.86 | -- | 51.32 | -- |
Data as of Mar 04 2026. Currency figures normalised to BioVie Inc's reporting currency: US Dollar USD
15.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Diametric Capital LPas of 31 Dec 2025 | 370.00k | 4.91% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 175.92k | 2.34% |
| Prosperity Wealth Management, Inc.as of 30 Sep 2025 | 143.50k | 1.91% |
| DRW Securities LLCas of 31 Dec 2025 | 128.36k | 1.70% |
| Prelude Capital Management LLCas of 31 Dec 2025 | 92.06k | 1.22% |
| The Philadelphia Trust Co. (Investment Management)as of 31 Dec 2025 | 75.01k | 1.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 60.22k | 0.80% |
| Geode Capital Management LLCas of 31 Dec 2025 | 55.38k | 0.74% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 37.56k | 0.50% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 28.02k | 0.37% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
